MEDIPOST CDMO service
MEDIPOST follows a strong quality policy that adheres to the latest GMP regulations and provide the best CDMO service to our clients based on our extensive experience in product approval obtainment and due diligence.
Latest News
Global Leader
in Stem Cell Therapeutics
0+
Number of registered patents in Korea and overseas
0+
Number of national R&D grants received in Korea
0
Number of private cord blood units stored
0%
Percentage of R&D staff
1st Generation Cord Blood-derived Stem Cell Products
CARTISTEM®
Treatment of knee cartilage defects including for patients with Knee Osteoarthritis
PNEUMOSTEM®
Preventive treatment of bronchopulmonary dysplasia(BPD)
PNEUMOSTEM® an allogeneic umbilical cord blood-derived mesenchymal stem cell product, is currently under development for the preventive treatment of Bronchopulmonary Dysplasia(BPD) in premature infants. Currently, Phase 2 clinical trial is ongoing in Korea and PNEUMOSTEM® has been Orphan Drug designated by US FDA and EMA. Recently, US FDA granted a Fast Track Designation for PNEUMOSTEM®.
2nd Generation Cord Blood-derived Stem Cell Products
SMUP-IA-01
Intra-articular Injectable treatment for osteoarthritis
SMUP-IV-01
Intra-venous infusion treatment for diabetic nephropathy
Global Leader in Stem Cell Therapeutics
As a global leader in biotechnology with cutting-edge Technologies in Stem Cell Therapeutics, MEDIPOST continues to innovate and challenge to tackle unmet medical needs.